Pravastatin and fenofibrate in combination (Pravafenix(®)) for the treatment of high-risk patients with mixed hyperlipidemia.

  • Michel Farnier
  • Published 2012 in Expert review of cardiovascular therapy


Pravafenix(®) is a fixed-dose combination of pravastatin 40 mg and fenofibrate 160 mg. The rationale for the use of Pravafenix is based on the increased residual cardiovascular risk observed for high-risk patients with either increased triglycerides or low HDL cholesterol levels despite statin monotherapy. This article reviews the current available… (More)
DOI: 10.1586/erc.12.37


Figures and Tables

Sorry, we couldn't extract any figures or tables for this paper.

Slides referencing similar topics